Journal of Gastroenterology

, Volume 45, Issue 10, pp 1014–1021

The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease

  • Hiromistu Ban
  • Akira Andoh
  • Hirotsugu Imaeda
  • Ayako Kobori
  • Shigeki Bamba
  • Tomoyuki Tsujikawa
  • Masaya Sasaki
  • Yasuharu Saito
  • Yoshihide Fujiyama
Original Article—Alimentary Tract

Abstract

Background

Multidrug resistance protein 4 (MRP4) functions as an efflux pump of nucleoside monophosphate analogs, such as 6-mercaptopurine (6-MP) and 6-thioguanine nucleotide (6-TGN). A single-nucleotide polymorphism in human MRP4 (rs3765534) dramatically reduces MRP4 function and results in the intracellular accumulation of 6-TGN. In this study, we investigated the association between MRP4 G2269A polymorphism and thiopurine sensitivity in Japanese IBD patients.

Methods

Direct sequencing of the MRP4 exon 18 was performed. The TPMT A719G and ITPase C94A polymorphisms were determined by polymerase-chain reaction-restriction fragment length polymorphism analyses.

Results

Of the 279 samples analyzed (44 healthy volunteers and 235 IBD patients), 68 samples showed a heterozygote of MRP4 G2269A and 7 carried a homozygote. The allelic frequency of MRP4 G2269A was 14.7%. In 130 IBD patients treated with azathioprine/6-MP, the white blood cell count was significantly lower in patients with the MRP4 variant alone (n = 26) than in patients with a wild allelotype (n = 74) (P = 0.014) or in patients with the ITPase variant alone (n = 22) (P = 0.0095). The 6-TGN levels were significantly higher in patients with the MRP4 variant alone than in patients with the wild allelotype (P = 0.049). Of the 15 patients who experienced leucopenia (<3 × 109/l), 7 patients carried the MRP4 variant. The odds ratio of carrying the MRP4 variant alone and having leukopenia was 3.30 (95% confidence interval 1.03–10.57, P = 0.036).

Conclusions

These results suggest that MRP4 G2269A might be a new factor accounting for thiopurine sensitivity in Japanese patients with IBD.

Keywords

MRP4 IBD Azathioprine 6-Mercaptopurine 

References

  1. 1.
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717–22.PubMedGoogle Scholar
  2. 2.
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000:CD000545.Google Scholar
  3. 3.
    Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006;41:10–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13:563–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:643–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783–800.CrossRefPubMedGoogle Scholar
  7. 7.
    Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24:1258–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Winter JW, Gaffney D, Shapiro D, Spooner RJ, Marinaki AM, Sanderson JD, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:1069–77.CrossRefPubMedGoogle Scholar
  10. 10.
    Lichtenstein GR, Sbreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex. 2006;71:351–401.PubMedGoogle Scholar
  11. 11.
    Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit. 2006;28:45–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease—relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008;65(1):69–77.CrossRefPubMedGoogle Scholar
  14. 14.
    Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res. 2000;448:91–5.PubMedGoogle Scholar
  15. 15.
    Ban H, Andoh A, Tanaka A, Tsujikawa T, Sasaki M, Saito Y, et al. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med. 2008;47:1645–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol. 2009;44:197–203.CrossRefPubMedGoogle Scholar
  17. 17.
    Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009;65:533–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn’s disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut. 2005;54:565.CrossRefPubMedGoogle Scholar
  19. 19.
    Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol. 2002;62:1321–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008;68:4983–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res. 2008;32:799–809.CrossRefPubMedGoogle Scholar
  23. 23.
    Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–302.CrossRefPubMedGoogle Scholar
  24. 24.
    Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, et al. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol. 2008;80:766–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Oevermann L, Scheitz J, Starke K, Kock K, Kiefer T, Dolken G, et al. Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009;124:2303–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-d-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001;276:33747–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608–14.PubMedGoogle Scholar
  28. 28.
    Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Pike MG, Franklin CL, Mays DC, Lipsky JJ, Lowry PW, Sandborn WJ. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001;757:1–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1373–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Hiromistu Ban
    • 1
  • Akira Andoh
    • 2
  • Hirotsugu Imaeda
    • 1
  • Ayako Kobori
    • 1
  • Shigeki Bamba
    • 1
  • Tomoyuki Tsujikawa
    • 1
  • Masaya Sasaki
    • 1
  • Yasuharu Saito
    • 1
  • Yoshihide Fujiyama
    • 1
  1. 1.Department of MedicineShiga University of Medical ScienceOtsuJapan
  2. 2.Division of Mucosal Immunology, Graduate School of MedicineShiga University of Medical ScienceOtsuJapan

Personalised recommendations